An observational study in Psoriasis and Psoriatic-arthritis, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Arthritis, Psoriatic with a site in Germany — 10 open to participants now, 28 under way, 18 of them phase 3. Arthritis, Psoriatic · Germany.
Among the 109 studies in Arthritis, Psoriatic with a site in Germany, this one is the 2nd largest by planned enrollment of the 19 observational ones that give a count, is the only one that started in 2008, is one of 19 observational ones, reaches primary completion later than 27 of the 27 other live ones, and was the 22nd registered.
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →10 of the 109 studies in Arthritis, Psoriatic with a site in Germany are open now. Recruiting first, the newest first:
Takeda · Sites in Germany, United States, Argentina and 17 more countries
Ages 18+
UCB Biopharma SRL · Sites in Germany, United States, Bulgaria and 3 more countries
Ages 18+
UCB Biopharma SRL · Sites in Germany, United States, Canada and 2 more countries
Ages 18+ · Women only
University of Bonn · Sites in Germany
Ages 18+ · Healthy volunteers
AbbVie · Sites in Germany, Argentina, Austria and 12 more countries
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 20 · Phase 3 57 · Phase 4 9
First in 2003; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,500 is above the median of 280 across 244 observational studies indexed under Arthritis, Psoriatic.
Median enrollment 357 across the 90 interventional studies, 500 across the 19 observational. Of the 77 that completed or were terminated, 58 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 109 have an industry lead sponsor. The 10 most frequent:
Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.
Universitätsklinikum Hamburg-Eppendorf has 1 study filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
10 of the studies in Arthritis, Psoriatic with a site in Germany that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 10 to your calendar (.ics) → With an account.
Among the 109 studies in Arthritis, Psoriatic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under real-world conditions is still missing. PsoBest, the German registry on the treatment of moderate to severe Pso and PsA started in 2008 and documents the long-term course of patients being administered any biologic or conventional systemic antipsoriatic drug authorized in Germany for the first time. The registry evaluates the long-term course of 3,500 patients with Pso and PsA treated with systemic antipsoriatics.
Background: Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under real-world conditions is still missing. PsoBest, the German registry on the treatment of moderate to severe Pso and PsA started in 2008 and documents the long-term course of patients being administered any biologic or conventional systemic antipsoriatic drug authorized in Germany for the first time.
Objectives: Observation and analysis of the following outcomes of treatment with systemic antipsoriatics:
Methods: The registry evaluates the long-term course of 3,500 patients with Pso and PsA treated with systemic antipsoriatics.The registry started for seven treatment arms: Fumaric acid, methotrexate, ciclosporin A, efalizumab, etanercept, infliximab and adalimumab. While efalizumab was withdrawn from the market, ustekinumab was included after authorization. Patients are included at first initiation of a given treatment and will remain in the registry for 5 years, regardless of subsequent therapy. Nationwide, dermatologic practices and hospital ambulances with expertise in systemic and biologic treatment consecutively enrol patients. Follow-ups will be every 3 to 6 months, comprising patient and treatment characteristics, clinical parameters, patient-defined benefit, quality of life and adverse events. Standardized questionnaires will be addressed to the patient and to the dermatologist 12 times at the dermatologic centres. In interim intervals, patients are directly contacted another 9 times by mail. PsoBest is member of the ENCePP network of psoriasis-registries (www.psonet.eu).
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
This study's planned enrollment of 3,500 is above the median of 280 across 244 observational studies indexed under Arthritis, Psoriatic.
Browse Arthritis, Psoriatic studies →Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.
Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients with plaque-type psoriasis or psoriatic-arthritis starting the first systemic treatment with authorized atipsoriatic drugs in Germany.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Drug: conventional systemic: Fumaric acid esters, including Dimethylfumarate, all dosages, frequencies and durations prescribed
Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed
Intervention: Biological and biosimilars: Etanercept, all dosages, frequencies and durations prescribed
Intervention: Biological and Biosimilars/-identicals: Infliximab, all dosages, frequencies and durations prescribed
Intervention: Biological and Biosimilars: Adalimumab, all dosages, frequencies and durations prescribed
Intervention: Biological and Biosimilars: Ustekinumab, all dosages, frequencies and durations prescribed
Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed
Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed
Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed
Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed
Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed
Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed
Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed
Intervention: Biological: Guselkumab all dosages, frequencies and durations prescribed
Intervention: Biological: Brodalumab, all dosages, frequencies and durations prescribed
Intervention: Biological: Tildrakizumab, all dosages, frequencies and durations prescribed
Intervention: Biological: systemic Risankizumab, all dosages, frequencies and durations prescribed
Intervention: Biological: Bimekizumab, all dosages, frequencies and durations prescribed
Intervention: JAK-Inhibitor: Tofacitinib, all dosages, frequencies and durations prescribed
Intervention: JAK-Inhibitor: Upadacitinib, all dosages, frequencies and durations prescribed
Intervention: JAK-Inhibitor: Deucravacitinib, all dosages, frequencies and durations prescribed
Intervention: Biological: Ixekizumab, all dosages, frequencies and durations prescribed
Intervention: no systemic treatment in observation episodes
Psoriasis Area Severity Index (PASI)
To evaluate clinical outcome of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
Time frame: every 6 month for 10 years
Dermatology Life Quality Index (DLQI)
To evaluate disease related quality of life of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
Time frame: every 3 month for 10 years
Adverse and serious adverse events
Risk for adverse events and serious adverse events for patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
Time frame: 6 month
Patient Benefit Index (PBI)
To evaluate the patient benefit of conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
Time frame: every 3 months for 10 years
EuroQol Questionnaire (EQ-5D)
To evaluate general state of health of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
Time frame: every 3 months for 10 years
Questionnaire on Supply Quality in Dermatology (FVQ-d)
To evaluate care characteristics of conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
Time frame: every 3 months for 10 years
Health Assessment Questionnaire (HAQ)
To evaluate arthritis severity of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
Time frame: every 6 months for 10 years
Patient Global Assessment (Skin: PaGAs, Arthritis: PaGAa)
To evaluate global severity of skin and arthritis in patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
Time frame: every 3 months for 10 years
Physician Global Assessment (Skin: PGAs, Arthritis: PGAa)
To evaluate global severity of skin and arthritis in patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
Time frame: every 6 months for 10 years
Disease Activity Score 28 (DAS 28), American College of Rheumatology Score (ACR20), Psoriatic Arthritic Response Criteria (PsARC)
To evaluate arthritis severity of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
Time frame: every 6 months for 10 years
Plan to share: Undecided
The record gives a start of Jan 2008, a primary completion of Dec 2032 and a completion of Dec 2032. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitätsklinikum Hamburg-Eppendorf →